AstraZeneca's Calquence Steps Up in First-Line CLL
Full Results Of First-Line Calquence Use In CLL
A PFS benefit and favorable tolerability profile associated with AstraZeneca’s BTK inhibitor acalabrutinib used first-line in CLL, when given alone or combined with obinutuzumab, may serve it well against entrenched competitors and BTK inhibitors in clinical development.
You may also be interested in...
The tireless pace of change in hemato-oncology was showcased in Orlando.
ArQule's lead candidate, ARQ 531, is a novel BTK inhibitor in Phase II development that could work in patients with B-cell malignancies resistant to existing BTK inhibitors like Imbruvica.